Soligenix Losses Widen Amid R&D Surge, Secures $7.5M in Public Offering

TL;DR

**SNGX is burning cash fast on R&D, but a recent $7.5M public offering buys them time to hit critical HyBryte milestones; watch for 2026 FLASH2 results.**

AI Summary

SOLIGENIX, INC. (SNGX) reported a net loss of $8,184,191 for the nine months ended September 30, 2025, a significant increase from the $5,279,210 net loss in the same period of 2024. The company generated no grant revenue in the nine months ended September 30, 2025, compared to $119,371 in 2024. Research and development expenses surged to $5,202,573 for the nine months ended September 30, 2025, up from $2,564,887 in 2024, primarily due to increased clinical trial activities for HyBryte. General and administrative expenses remained relatively stable at $3,168,297 in 2025 versus $3,162,115 in 2024. Cash and cash equivalents increased to $10,525,335 as of September 30, 2025, from $7,819,514 at December 31, 2024, largely driven by $10,231,191 in financing activities, including a September 2025 public offering that raised $7,498,522. The company is actively enrolling patients in its Phase 3 FLASH2 study for HyBryte in CTCL and plans to expand synthetic hypericin development into psoriasis (SGX302) and dusquetide into Behcet's Disease (SGX945). Management believes it has sufficient resources for at least the next twelve months.

Why It Matters

This filing reveals Soligenix's deepening losses and increased R&D spend, primarily driven by the critical Phase 3 FLASH2 study for HyBryte. For investors, the successful completion and regulatory approval of HyBryte are paramount, as the company currently lacks revenue. The significant capital raise through a public offering in September 2025, totaling $7,498,522, provides a lifeline for continued operations and clinical development, but also indicates ongoing dilution. Employees and customers are impacted by the progress of these drug candidates, particularly HyBryte for CTCL, which addresses an unmet medical need. In a competitive biopharmaceutical landscape, Soligenix's ability to secure partnerships and government funding will be crucial for its long-term viability.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $242,154,943 and a net loss of $8,184,191 for the nine months ended September 30, 2025, indicating a history of significant losses. While management believes it has sufficient resources for the next twelve months, this relies on future financing and potential partnerships, which are not assured. The lack of current revenue and heavy reliance on successful clinical trials for HyBryte (anticipated top-line results in H2 2026) present substantial operational and financial risks.

Analyst Insight

Investors should closely monitor the progress of the Phase 3 FLASH2 study for HyBryte, with top-line results expected in the second half of 2026, as this is the primary value driver. Given the high burn rate and reliance on future financing, consider the potential for further dilution. Evaluate the company's ability to secure additional government grants and strategic partnerships to mitigate financial risk.

Financial Highlights

debt To Equity

0.49

revenue

$0

operating Margin

N/A

total Assets

$11,293,917

total Debt

$3,695,941

net Income

-$8,184,191

eps

-$0.58

gross Margin

N/A

cash Position

$10,525,335

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $8,184,191 — Net Loss (for the nine months ended September 30, 2025, increased from $5,279,210 in 2024)
• $5,202,573 — Research and Development Expenses (for the nine months ended September 30, 2025, up from $2,564,887 in 2024)
• $10,525,335 — Cash and Cash Equivalents (as of September 30, 2025, up from $7,819,514 at December 31, 2024)
• $7,498,522 — Proceeds from September 2025 Public Offering (contributed to financing activities)
• $242,154,943 — Accumulated Deficit (as of September 30, 2025)
• $7,521,449 — Cash Used in Operating Activities (for the nine months ended September 30, 2025)
• 9,861,130 — Common Shares Outstanding (as of September 30, 2025, increased from 2,514,499 at December 31, 2024)
• $0.58 — Basic and Diluted Net Loss Per Share (for the three months ended September 30, 2025, improved from $0.78 in 2024)

Key Players & Entities

• SOLIGENIX, INC. (company) — registrant
• HyBryte (company) — proprietary name of SGX301, a novel photodynamic therapy
• European Medicines Agency (regulator) — agreed on key design components for FLASH2 study
• U.S. Food and Drug Administration (regulator) — awarded Orphan Products Development grant
• National Institute of Allergy and Infectious Diseases (regulator) — government grant and contract funding
• Biomedical Advanced Research and Development Authority (regulator) — government grant and contract funding
• Defense Threat Reduction Agency (regulator) — government grant and contract funding
• Nasdaq Capital Market (regulator) — exchange where common stock is registered
• Pontifax (company) — converted debt principal into common stock in 2024

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $242,154,943 as of September 30, 2025. This indicates a history of net losses, and the company may need to continue seeking external financing to fund its operations and development activities.
• Dependence on Future Financing [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional funding. While cash and cash equivalents increased to $10,525,335 as of September 30, 2025, driven by a public offering, ongoing clinical trials and development require substantial capital.
• Clinical Trial Risks [high — operational]: The company is actively engaged in clinical trials for its drug candidates, such as HyBryte. These trials are subject to inherent risks, including potential delays, unexpected side effects, and failure to demonstrate efficacy or safety, which could significantly impact development timelines and commercialization prospects.
• Drug Development and Approval Process [high — regulatory]: The development and commercialization of pharmaceutical products are subject to stringent regulatory review and approval processes by agencies like the FDA. Delays or failures in obtaining regulatory approval for HyBryte or other pipeline candidates would materially adversely affect the company's business.
• Increased R&D Expenses [medium — operational]: Research and development expenses surged to $5,202,573 for the nine months ended September 30, 2025, from $2,564,887 in the prior year period, primarily due to increased clinical trial activities. This significant increase in spending, while necessary for development, puts pressure on the company's financial resources.
• Dilution from Share Issuances [medium — financial]: The company's common shares outstanding increased significantly from 2,514,499 at December 31, 2024, to 9,861,130 at September 30, 2025, largely due to a public offering. This substantial increase in shares can dilute existing shareholders' ownership.
• Competition in Therapeutic Areas [medium — market]: Soligenix operates in competitive therapeutic areas, including cutaneous T-cell lymphoma (CTCL), psoriasis, and Behcet's Disease. The success of its product candidates will depend on their ability to demonstrate a competitive advantage over existing treatments or therapies in development by other companies.
• Cash Burn Rate [medium — financial]: The company used $7,521,449 in operating activities for the nine months ended September 30, 2025. While cash increased due to financing, the operating cash burn rate remains a critical factor for future liquidity.

Industry Context

Soligenix operates in the highly competitive biotechnology and pharmaceutical sector, focusing on developing treatments for rare and orphan diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include advancements in targeted therapies and the increasing demand for treatments for unmet medical needs.

Regulatory Implications

The company's success is heavily dependent on navigating the complex and lengthy drug approval process by regulatory bodies like the FDA. Any delays or failures in obtaining approval for its pipeline candidates, such as HyBryte, SGX302, or SGX945, would have a material adverse impact on its future prospects.

What Investors Should Do

1. Monitor clinical trial progress and results for HyBryte (CTCL), SGX302 (psoriasis), and SGX945 (Behcet's Disease).
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape and potential market penetration for Soligenix's drug candidates.
4. Review management's commentary on the sufficiency of resources for the next twelve months.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $8,184,191 and significant increase in R&D expenses to $5,202,573. Cash and cash equivalents stood at $10,525,335.
• 2025-09-30: September 2025 Public Offering — Raised $7,498,522, contributing significantly to the increase in cash and cash equivalents and supporting ongoing operations and development.
• 2025-09-30: Common Shares Outstanding — Increased to 9,861,130 from 2,514,499 at December 31, 2024, indicating significant equity financing and potential dilution.
• 2024-09-30: Nine months ended September 30, 2024 — Reported a net loss of $5,279,210 and R&D expenses of $2,564,887. Generated $119,371 in grant revenue.
• 2024-12-31: December 31, 2024 — Cash and cash equivalents were $7,819,514. Common shares outstanding were 2,514,499.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability and its reliance on external funding to cover losses.)

Research and development expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Key indicator of investment in future growth and innovation, particularly relevant for biotech and pharmaceutical companies.)

Cash and cash equivalents

The most liquid assets held by a company, including physical currency, checking account balances, and short-term, highly liquid investments. (Measures a company's immediate liquidity and its ability to meet short-term obligations.)

Public offering

The sale of shares of stock to the general public, typically to raise capital for the company. (A common method for companies, especially those in development stages, to secure funding for operations and expansion.)

Net loss

The total expenses of a company exceed its total revenues over a specific period. (Indicates the company's profitability over the reporting period.)

CTCL

Cutaneous T-cell lymphoma, a type of non-Hodgkin lymphoma that affects the skin. (The primary indication for Soligenix's lead drug candidate, HyBryte.)

Debt-to-equity ratio

A financial ratio that indicates the relative proportion of shareholders' equity and debt used to finance a company's assets. (Measures financial leverage and risk; a higher ratio indicates greater reliance on debt financing.)

Operating expenses

The costs a business incurs in its normal course of operations, excluding cost of goods sold. (Includes R&D and G&A expenses, crucial for understanding the cost structure and operational efficiency.)

Year-Over-Year Comparison

Compared to the prior year period, Soligenix reported a significant increase in its net loss for the nine months ended September 30, 2025, to $8,184,191 from $5,279,210. This was driven by a substantial surge in research and development expenses, which more than doubled to $5,202,573, primarily due to increased clinical trial activities. Grant revenue has ceased entirely, dropping from $119,371 to $0. While cash reserves have improved to $10,525,335, largely from financing activities including a public offering, the company's accumulated deficit has also grown to $242,154,943. New risks related to the increased R&D spend and the ongoing need for financing are more pronounced.

Key Financial Figures

• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
• $35 m — value of listed securities of at least $35 million, or net income of $500,000 from c
• $500,000 — at least $35 million, or net income of $500,000 from continuing operations in the most

Filing Documents

• sngx-20250930x10q.htm (10-Q) — 1773KB
• sngx-20250930xex31d1.htm (EX-31.1) — 18KB
• sngx-20250930xex31d2.htm (EX-31.2) — 19KB
• sngx-20250930xex32d1.htm (EX-32.1) — 8KB
• sngx-20250930xex32d2.htm (EX-32.2) — 11KB
• 0001104659-25-108475.txt ( ) — 6991KB
• sngx-20250930.xsd (EX-101.SCH) — 32KB
• sngx-20250930_cal.xml (EX-101.CAL) — 38KB
• sngx-20250930_def.xml (EX-101.DEF) — 162KB
• sngx-20250930_lab.xml (EX-101.LAB) — 323KB
• sngx-20250930_pre.xml (EX-101.PRE) — 231KB
• sngx-20250930x10q_htm.xml (XML) — 1460KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4

Controls and Procedures

Controls and Procedures 46 Part II OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 46 Item 1A

Risk Factors

Risk Factors 46 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 5 Other Information 47 Item 6 Exhibits 48

SIGNATURES

SIGNATURES 49 i Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

- FINANCIAL STATEMENTS

ITEM 1 - FINANCIAL STATEMENTS Soligenix, Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, December 31, 2025 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 10,525,335 $ 7,819,514 Deferred issuance cost — 103,847 Prepaid expenses and other current assets 355,578 905,269 Total current assets 10,880,913 8,828,630 Security deposit 22,777 22,777 Office furniture and equipment, net 7,812 6,113 Right-of-use lease assets 382,415 108,963 Total assets $ 11,293,917 $ 8,966,483 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 1,206,796 $ 667,896 Accrued expenses 2,031,272 2,359,339 Accrued compensation 72,819 336,442 Lease liabilities, current 111,134 111,862 Convertible debt — 1,372,873 Total current liabilities 3,422,021 4,848,412 Non-current liabilities: Lease liabilities, net of current portion 273,920 — Total liabilities 3,695,941 4,848,412 Commitments and contingencies (Note 6) Shareholders' equity: Preferred stock, 350,000 shares authorized; none issued or outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ .001 par value; 75,000,000 shares authorized; 9,861,130 and 2,514,499 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 9,861 2,514 Additional paid-in capital 249,697,269 238,040,520 Accumulated other comprehensive income 45,789 45,789 Accumulated deficit ( 242,154,943 ) ( 233,970,752 ) Total shareholders' equity 7,597,976 4,118,071 Total liabilities and shareholders' equity $ 11,293,917 $ 8,966,483 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents Soligenix, Inc. and Subsidiaries Condensed Consolidated Statements of Operations For the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) Three

View Full Filing

View this 10-Q filing on SEC EDGAR